

Stockholm, 20 March 2012

CFO Lars Sandström to leave Sobi

CFO Lars Sandström will leave Sobi during the summer 2012 to return to his former employer Scania. The recruitment of a new CFO has been initiated.

Lars Sandström joined Sobi in 2010 and was appointed CFO in February 2011.

"We thank Lars for his contributions to Sobi and wish him well in his future endeavors, says Geoffrey McDonough, President and CEO of Sobi.

For further information, please contact:

Åsa Stenqvist, Head of Communications
Tel.: +46 8 697 21 88

Swedish Orphan Biovitrum (Sobi)

Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the health of rare disease patients and their families. The product portfolio comprises about 45 marketed products as well as projects in the late clinical phase. Key therapeutic areas are Inflammation and Genetics & Metabolism. In 2011, Sobi had revenues of SEK 1.9 billion and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.

The information above has been published pursuant to the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on 20 March, 2012 at 12.15 CET.